Please login to the form below

Not currently logged in
Email:
Password:

Spravato

This page shows the latest Spravato news and features for those working in and with pharma, biotech and healthcare.

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

J&J’s ponesimiod tops Aubagio in head-to-head MS trial

The company does however have a resurgent central nervous system (CNS) therapeutic category following the approval of Spravato(esketamine), a nasal spray for treatment-resistant depression that J&J reckons can

Latest news

  • Stung by critics, J&J says antidepressant Spravato saves money Stung by critics, J&J says antidepressant Spravato saves money

    Responds to ICER cost effectiveness ruling. Johnson &Johnson insists its nasal spray antidepressant Spravato can reduce the cost of caring for treatment-resistant depression (TRD) compared to oral drugs, in a ... For its part, J&J insists its new cost-per

  • Depression drug failure adds to Allergan's woes Depression drug failure adds to Allergan's woes

    The misfiring of rapastinel is a major blow for the company’s most important late-stage candidate, and is a clear contrast to J&J’s rival treatment Spravato (esketamine), which

  • J&J’s Spravato breaks depression drought at FDA J&J’s Spravato breaks depression drought at FDA

    The FDA has approved Johnson &Johnson’s Spravato for treatment-resistant depression, making it the first new-mechanism antidepressant to be licensed in decades. ... Spravato should make the add-on therapy much more accessible and affordable, at least

  • FDA panel backs J&J’s new-class antidepressant FDA panel backs J&J’s new-class antidepressant

    The nasal spray formulation of esketamine – a derivative of the anaesthetic ketamine that has the proposed name Spravato – was backed by a 14-2 vote by an FDA advisory committee yesterday

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 700 experts delivering world-class...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics